Tamsulosin: An update of its role in the management of lower urinary tract symptoms

Drugs

Volumn 62, Issue 1, 2002, Pages 135-167

  Lyseng Williamson, Katherine A ^a   Jarvis, Blair ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Benign prostatic hyperplasia; Lower urinary tract symptoms; Pharmacodynamics; Pharmacokinetics; Tamsulosin; Therapeutic use; 1 adrenoceptor antagonists

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; CHLORMADINONE; PLACEBO; TAMSULOSIN; TERAZOSIN;

ASTHENIA; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; HEADACHE; HUMAN; INFECTION; MALE GENITAL SYSTEM DISEASE; MULTICENTER STUDY; PHARMACODYNAMICS; PHARYNGITIS; PROSTATE CANCER; REVIEW; RHINITIS; SEXUAL FUNCTION; TREATMENT OUTCOME; URETHRA DISEASE; URINARY TRACT DISEASE; VERTIGO;

EID: 0036182291     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262010-00006     Document Type: Review

References (140)

1. Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia
2. International consultation on urological diseases: A decade of progress
3. How do symptoms indicative of BPH progress in real life practice? The UK experience
4. Comprehensive patient evaluation for benign prostatic hyperplasia
5. Obstructive uropathy in the male
6. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia
7. The prevalence of prostatism: A population-based survey of urinary symptoms
8. High prevalence of benign prostatic hypertrophy in the community
9. International comparison of the community prevalence of symptoms of prostatism in four countries
10. Similar levels of urological symptoms have similar impact on Scottish and American men - Although Scots report less symptoms
11. Benign prostatic hyperplasia: Use of drug therapy in primary care
12. Clinical manifestations of benign prostatic hyperplasia
13. The International Continence Society 'benign prostatic hyperplasia' study: The bothersomeness of urinary symptoms
14. Urinary symptoms in the community: How bothersome are they?
15. α-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it
16. 1-adrenoreceptor antagonists in the treatment of lower urinary tract symptoms
17. α-Blockers and lower urinary tract function: More than smooth muscle relaxation?
18. 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH)
19. Tamsulosin: A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia
20. 1-Blockers for BPH: Are there differences?
21. 1-adrenoceptors: Consensus update
22. 1-adrenoceptor antagonists in benign prostatic hyperplasia: Rationale and clinical experience
23. 1d subtype in filling symptoms and effects of ageing on vascular expression
24. 1-Adrenergic receptor subtypes in human detrusor
25. 1 adrenergic receptor subtypes in human prostate
26. 1-adrenergic receptor subtypes at four distinct levels
27. 1-adrenoceptor subtypes and in human prostate
28. Do we know everything about alpha-blockade in the management of lower urinary tract symptoms?
29. 1-adrenergic receptor subtypes in lower urinary tract symptoms
30. 1-adrenergic receptors by vessel bed and age
31. 1-adrenoceptor
32. 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy
33. 1-Adrenoceptor subtype selectivity of tamsulosin: Studies using livers from different species
34. 1-adrenergic receptor subtypes expressed in human embryonic kidney 293 cells: Antagonist potencies and sensitivity to alkylating agents
35. 1-adrenoceptor subtypes
36. 1-adrenergic receptor subtypes
37. Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics
38. 1D-adrenoceptor subtypes
39. 1-adrenergic selectivity?
40. 1-adrenoceptor antagonist binding in human prostate and aorta
41. 1-antagonist selective for the lower urinary tract: In vitro studies
42. 1-adrenoceptors in rat tissues in relation to the plasma concentration
43. 1 adrenoceptors in rat tissues in relation to the pharmacokinetics
44. Human prostate-artery selectivity of tamsulosin, doxazosin and alfuzosin
45. Effect of the optimal isomers of YM-12617 on increased intra-urethral pressure induced by phenylephrine in anaesthetized dogs
46. Alpha-1 adrenoceptor antagonist effects of the optimal isomers of YM-12617 in rabbit lower urinary tract and prostate
47. Medical management of benign prostatic hyperplasia: A canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate
48. Pharmacological antagonism of α-adrenergic agonist induced increases in canine intraurethral pressure in vivo
49. Benign prostatic hyperplasia: An overview
50. The use of ultrasound estimated bladder weight (UEBW) in evaluation of change in bladder hypertrophy during treatment with an α1 blocker
51. Ultrasonic estimation of bladder weight as a measure of bladder hypertrophy in men with infravesical obstruction: A preliminary report
52. Noninvasive quantitative estimation of infravesical obstruction using ultrasonic measurement of bladder weight
53. 1A-adrenergic antagonist
54. 1-adrenoceptors
55. 1adrenoceptors in humans
56. 1-adrenergic receptors
57. 1-adrenoceptor antagonism by tamsulosin and terazosin
58. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing
59. Tamsulosin: Effect on PSA levels in 3-month placebo-controlled studies and long-term follow-up of these studies
60. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: An open-label single-dose and multiple-dose study
61. Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans
62. 1A-adrenoceptor antagonist tamsulosin in humans: Comparison with data from interspecies scaling
63. Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function
64. Absorption, metabolism and excretion of tamsulosin hydrochloride in man
65. 1-adrenoceptor blocker tamsulosin in human liver microsomes
66. Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes
67. A 6-month large-scale study into the safety of tamsulosin
68. 1c-adrenoceptor antagonist: A randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH)
69. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia
70. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia
71. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia
72. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial
73. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia
74. Long-term efficacy of tamsulosin: Results of a 6-year experience
75. A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH)
76. Use of an αl- blocker, YM617, in the treatment of benign prostatic hypertrophy
77. Clinical evaluation of YM617 on bladder outlet obstruction associated with benign prostatic hypertrophy - A double-blind, multicentre study compared with placebo
78. Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia
79. 1-Blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: What are file relevant differences in randomised controlled trials?
80. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia)
81. 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: Studies on tamsulosin and terazosin in Chinese patients
82. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia
83. Tamsulosin: Does comorbidity affect outcomes?
84. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms
85. Effect of tamsulosin on AUA symptom score and BPH impact index as a function of symptom severity in patients with benign prostatic hyperplasia
86. 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia)
87. Tamsulosin in men with confirmed bladder outlet obstruction: A clinical and urodynamic analysis from a single centre in New Zealand
88. Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: Results of a pilot study
89. Temporal resolution of urinary morbidity following prostate brachytherapy
90. A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH
91. 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses
92. Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia
93. Efficacy and tolerability of tamsulosin in patients <65 years and ≥65 years with benign prostatic hyperplasia
94. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate
95. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer
96. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma
97. Tamsulosin: Real life clinical experience in 19,365 patients
98. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
99. Finasteride and tamsulosin used in benign prostatic hypertrophy: A review of the prescription-event monitoring data
100. Tamsulosin 0.4 mg once daily: Tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH)
101. Tamsulosin 0.4 mg once daily: Effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
102. Tamsulosin: Effect on sexual function in almost 3000 patients with LUTS managed in real life practice in Spain
103. Orthostatic effects of alfuzosin twice daily vs. tamsulosin once daily in the morning
104. The effects of tamsulosin on vital signs in two multicenter, placebo- controlled studies
105. Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: Interactions with antihypertensive therapy
106. The pharmacovigilance of tamsulosin: Event data on 12484 patients
107. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: Does co-morbidity alter tolerability?
108. 1A-adrenergic receptor antagonist, shows lack of orthostatic hypotensive effects
109. Investigation of the effects of tamsulosin on blood pressure in normotensive, controlled hypertensive, and uncontrolled hypertensive men with benign prostatic byperplasia
110. Low incidence of orthostatic changes in long-term use of tamsulosin
111. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: Pharmacodynamic effect
112. Does the time of administration (morning or evening) affect the tolerability or efficacy of tamsulosin?
113. The Agency for Health Care Policy and Research. Clinical guidelines for the diagnosis and treatment of benign prostatic prostatic hyperplasia
114. Real-life experience in lower urinary tract symptom management
115. Benign prostatic hyperplasia: Practical treatment guidelines
116. Symptom status and quality of life following prostatectomy
117. Mangement of symptomatic BPH in the US: Who is treated and how?
118. Transurethral prostatectomy: Practice aspects of the dominant operation in American urology
119. BPHH: New guidelines based on symptoms and patient preference
120. 3-Year follow up of urinary symptoms after transurethral resection of the prostate
121. α-Adrenoceptor antagonists in the treatment of benign prostatic hyperplasia
122. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
123. Pharmacologic therapy for prostatism
124. Randomised placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia
125. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients
126. What's the benefit of combining tamsulosin with Serenoa repens?
127. The effect of finasteride in men with benign prostatic hyperplasia
128. Results of the PREDICT (Prospective Randomised European Doxazosin and Combination) study of medical therapy for BPH
129. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia
130. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
131. Alpha blockers: Are all created equal?
132. Worldwide experience with alfuzosin and tamsulosin
133. 2-adrencoceptor subtypes: Therapeutic implications